Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
BMS 247615
Bcl-xL and Mcl-1 cooperate to protect cancer cells against apoptosis and their concomitant inhibition leads to massive apoptosis even in the absence of chemotherapy
It was also used in animal models to treat FOP and ectopic ossification
is a histamine H2-receptor antagonist that inhibits stomach acid production
13)/t9-/m1/s1
Sunitinib Malate Size:Solid 2 mg BMS 247615Sunitinib, also known as SU11248, is the orally bioavailable malate salt of an indolinone based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet derived